Roger J. Brideau

1.8k total citations · 1 hit paper
32 papers, 1.5k citations indexed

About

Roger J. Brideau is a scholar working on Epidemiology, Oncology and Genetics. According to data from OpenAlex, Roger J. Brideau has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 11 papers in Oncology and 10 papers in Genetics. Recurrent topics in Roger J. Brideau's work include Respiratory viral infections research (13 papers), Cytomegalovirus and herpesvirus research (13 papers) and Virus-based gene therapy research (8 papers). Roger J. Brideau is often cited by papers focused on Respiratory viral infections research (13 papers), Cytomegalovirus and herpesvirus research (13 papers) and Virus-based gene therapy research (8 papers). Roger J. Brideau collaborates with scholars based in United States, Brazil and United Kingdom. Roger J. Brideau's co-authors include W. Robert McMaster, Philip B. Carter, Donald W. Mason, Abigail Williams, Michael W. Wathen, Nancee L. Oien, D R Thomsen, Mary L. Knechtel, Todd A. Hopkins and Fred L. Homa and has published in prestigious journals such as Journal of Virology, Journal of Medicinal Chemistry and The Journal of Infectious Diseases.

In The Last Decade

Roger J. Brideau

32 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Two subsets of rat T lymphocytes defined with monoclonal antibodies

1980 630 citations Roger J. Brideau et al. profile →

Peers

Countries citing papers authored by Roger J. Brideau

Since Specialization

Citations

This map shows the geographic impact of Roger J. Brideau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger J. Brideau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger J. Brideau more than expected).

Fields of papers citing papers by Roger J. Brideau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger J. Brideau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger J. Brideau. The network helps show where Roger J. Brideau may publish in the future.

Co-authorship network of co-authors of Roger J. Brideau

This figure shows the co-authorship network connecting the top 25 collaborators of Roger J. Brideau. A scholar is included among the top collaborators of Roger J. Brideau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger J. Brideau. Roger J. Brideau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC 2012 ·Bioorganic & Medicinal Chemistry Letters ·Joseph S. Warmus, Cheryl L. Quinn, Clarke Taylor, Sean T. Murphy, Timothy A. Johnson, Chris Limberakis, Daniel F. Ortwine, Joel C. Bronstein, (unknown), John D. Knafels, Sandra Lightle, Igor Mochalkin, Roger J. Brideau, Terry Podoll	28
2	Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamides with broad-spectrum human herpesvirus polymerase inhibition 2008 ·Bioorganic & Medicinal Chemistry Letters ·Mark E. Schnute, Roger J. Brideau, Sarah A. Collier, (unknown), Todd A. Hopkins, Mary L. Knechtel, Nancee L. Oien, (unknown), (unknown), (unknown), Michael W. Wathen, (unknown)	18
3	2-Aryl-2-hydroxyethylamine substituted 4-oxo-4,7-dihydrothieno[2,3-b]pyridines as broad-spectrum inhibitors of human herpesvirus polymerases 2007 ·Bioorganic & Medicinal Chemistry Letters ·Mark E. Schnute, David Anderson, Roger J. Brideau, Fred L. Ciske, Sarah A. Collier, (unknown), MariJean Eggen, Michaël Génin, Todd A. Hopkins, Thomas M. Judge, (unknown), Mary L. Knechtel, Sajiv K. Nair, James A. Nieman, Nancee L. Oien, (unknown), Steven P. Tanis, Valerie Vaillancourt, Michael W. Wathen, (unknown)	36
4	7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: Synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymerase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Scott D. Larsen, Zhi‐Jun Zhang, (unknown), Peter R. Manninen, Douglas C. Rohrer, Michael J. Hageman, Todd A. Hopkins, Mary L. Knechtel, Nancee L. Oien, Bob D. Rush, Francis J. Schwende, Kevin Stefanski, (unknown), Karen F. Wilkinson, (unknown), Michael W. Wathen, Roger J. Brideau	8
5	Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity 2004 ·Antiviral Research ·Caroll B. Hartline, Emma A. Harden, (unknown), Nicole L. Kushner, Roger J. Brideau, Earl R. Kern	56
6	Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU‐183792, a 4‐oxo‐dihydroquinoline 2002 ·Journal of Medical Virology ·Mary L. Knechtel, Audris Huang, Valerie Vaillancourt, Roger J. Brideau	19
7	Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase 2000 ·Bioorganic & Medicinal Chemistry Letters ·Valerie Vaillancourt, (unknown), (unknown), Roger J. Brideau, (unknown), Mary L. Knechtel, Nancee L. Oien, (unknown), Yoshihiko Yagi, Michael W. Wathen	23
8	Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis 1999 ·International Journal of Immunopharmacology ·Steven M. Vroegop, D L Chapman, (unknown), (unknown), Roger J. Brideau, (unknown), C. J. Dunn, Stephen Buxser	9
9	Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit 1994 ·Vaccine ·Nancee L. Oien, Roger J. Brideau, Edward E. Walsh, Michael W. Wathen	46
10	Purification of a Recombinant Human Respiratory Syncytial Virus Chimeric Glycoprotein Using Reversed-Phase Chromatography and Protein Refolding in Guanidine Hydrochloride 1994 ·Protein Expression and Purification ·Peter A. Wells, Robert Garlick, (unknown), (unknown), Roger A. Poorman, Roger J. Brideau, Michael W. Wathen	1
11	Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3 1993 ·Journal of General Virology ·Fred L. Homa, Roger J. Brideau, (unknown), D R Thomsen, Robert A. Olmsted, Michael W. Wathen	20
12	Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity 1993 ·Vaccine ·Nancee L. Oien, Roger J. Brideau, D R Thomsen, Fred L. Homa, Michael W. Wathen	8
13	A Human Respiratory Syncytial Virus (RSV) Primate Model of Enhanced Pulmonary Pathology Induced with a Formalin-Inactivated RSV Vaccine but Not a Recombinant FG Subunit Vaccine 1993 ·The Journal of Infectious Diseases ·Thomas J. Kakuk, Kenneth F. Soike, Roger J. Brideau, Renee M. Zaya, Suzanne Cole, Jinyong Zhang, E. D. Roberts, Peter A. Wells, Michael W. Wathen	80
14	A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice 1991 ·Vaccine ·Roger J. Brideau, Michael W. Wathen	13
15	Vaccination of Cotton Rats with a Chimeric FG Glycoprotein of Human Respiratory Syncytial Virus Induces Minimal Pulmonary Pathology on Challenge 1991 ·The Journal of Infectious Diseases ·Michael W. Wathen, Thomas J. Kakuk, Roger J. Brideau, (unknown), Suzanne Cole, Renee M. Zaya	42
16	Production, Characterization, and Utility of Monoclonal Antibodies Which React with a Novel Chimeric Glycoprotein of Human Respiratory Syncytial Virus Termed FG 1989 ·Hybridoma ·Roger J. Brideau, Rodney R. Walters, Michael W. Wathen	2
17	Characterization of a Novel Human Respiratory Syncytial Virus Chimeric FG Glycoprotein Expressed Using a Baculovirus Vector 1989 ·Journal of General Virology ·Michael W. Wathen, Roger J. Brideau, D R Thomsen, Brian R. Murphy	43
18	Immunization of Cotton Rats with the Human Respiratory Syncytial Virus F Glycoprotein Produced Using a Baculovirus Vector 1989 ·The Journal of Infectious Diseases ·Michael W. Wathen, Roger J. Brideau, D R Thomsen	51
19	Monoclonal antibodies that cross-react with the E1 glycoprotein of different alphavirus serogroups: characterization including passive protection in vivo 1989 ·Virus Research ·Carl J. Wust, (unknown), (unknown), (unknown), Roger J. Brideau, (unknown), Alex Brown	14
20	Antiproliferative Action of Interferon on Murine LI210 Cells: Interrelationship with Prostaglandins 1983 ·Journal of Interferon Research ·Roger J. Brideau, Dale A. Stringfellow	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact